Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069264 | 0.91 | MEN1 (0.37) | PLA2G4AALDH1A1HCRTR1HCRTR2POLB | |
| SCHEMBL5043763 | 0.87 | ALDH1A1 (0.37) | PLA2G4AALDH1A1POLBLMNAMAPT | |
| SCHEMBL5043782 | 0.85 | CTSK (0.36) | PLA2G4AALDH1A1SMN1; SMN2LMNATP53 | |
| SCHEMBL5133265 | 0.83 | ALDH1A1 (0.41) | ALDH1A1POLBSMN1; SMN2TP53 | |
| SCHEMBL5039361 | 0.77 | TSHR (0.38) | ALDH1A1POLBMAPK1SMN1; SMN2LMNA | |
| SCHEMBL5039350 | 0.70 | HPGD (0.45) | ALDH1A1POLBMAPK1SMN1; SMN2LMNA | |
| SCHEMBL5039641 | 0.68 | ALDH1A1 (0.52) | ALDH1A1POLBSMN1; SMN2LMNAMAPT | |
| SCHEMBL5045868 | 0.68 | TSHR (0.39) | ALDH1A1POLBMAPK1SMN1; SMN2LMNA | |
| SCHEMBL6068958 | 0.68 | ALDH1A1 (0.41) | ALDH1A1POLBMAPK1SMN1; SMN2LMNA | |
| SCHEMBL5043897 | 0.66 | MAPT (0.41) | ALDH1A1POLBLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583762-B1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7135488-B2 | Pyrrolyl-thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1583762-A1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004060888-A1 | NOVEL CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | CNR1, CNR2, NPY1R | PLA2G4A 1747/4885ALDH1A1 959/4885HCRTR1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.